Key result
Anti-PARP activity detected by a PARPSso-based immunotest was significantly higher in active SLE versus inactive disease (p=0.001) and significantly correlated with disease activity (p<0.001).
Why the study?
Does an immunotest using PARPSso accurately detect anti-PARP antibodies and correlate with disease activity in patients with SLE?
Cross-Sectional (n=44)
Does an immunotest using PARPSso accurately detect anti-PARP antibodies and correlate with disease activity in patients with SLE?
An immunotest using PARPSso can detect anti-PARP antibodies, which correlate with disease activity in patients with systemic lupus erythematosus.
Answers are grounded in this paper and cite their sources.
Anti-PARP via PARPSso immunotest may mark SLE activity; hypothesis-generating and requires prospective validation before any clinical role.
The clinical usefulness of an immunotest was evaluated by using purified poly(adenosine diphosphate (ADP)-ribose) polymerase from Sulfolobus solfataricus (PARPSso) as an antigen to detect the presence of abnormal anti-PARP antibodies in the sera of patients with systemic lupus erythematosus (SLE) at different clinical stages. Sera from 44 patients with SLE, subgrouped on the basis of disease activity (16 with inactive disease, 28 with active disease) were analysed with a new immunotest to detect anti-PARP antibodies, and with an immunofluorescent (IIF) assay for antinuclear antibodies (ANA) detection. ANA detection by IIF revealed that sera of healthy subjects were negative, whereas sera from patients with SLE were positive in all cases (13 positive at 1:80, 15 at 1:160, 15 at 1:320, 1 at 1:640, v/v). Anti-PARP activity was higher in ANA-positive patients than in controls (p = 0.005). Within the group of SLE sera, disease and anti-PARP activity was increased more significantly in patients with active than in those with inactive disease (p < 0.001 and p = 0.001, respectively). Correlation between anti-PARP and disease activity in SLE patients was statistically significant (p < 0.001). PARPSso seems to be suitable for detecting anti-PARP antibodies and could play a role as a serological marker of disease activity in patients with SLE.
No takes yet. Share an insight, caveat, or question.
Mennella et al. (2009) conducted a cross-sectional in Systemic lupus erythematosus (SLE) (n=44). Immunotest using PARPSso as an antigen vs. Healthy controls and patients with inactive SLE was evaluated on Correlation between anti-PARP antibodies and disease activity (p=<0.001). Anti-PARP activity detected by a PARPSso-based immunotest was significantly higher in active SLE versus inactive disease (p=0.001) and significantly correlated with disease activity (p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: